ID: h-69acbe8b
Hypothesis
P2X7 Receptor Antagonism to Block ATP-Induced Microglial Pyroptosis
P2X7 Receptor Antagonism to Block ATP-Induced Microglial Pyroptosis.
🧬 P2RX7 (P2X7 receptor) → PANX1 → NLRP3 → Caspase-1/Gasdermin D🩺 immunomics🎯 Composite 45%💱 $0.49▲8.8%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 4 oppose
🧪 Overview
P2X7 Receptor Antagonism to Block ATP-Induced Microglial Pyroptosis
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Extracellular<br/>ATP"]
B["P2X7 Receptor<br/>Activation"]
C["PANX1 Pannexin<br/>Channel Opening"]
D["NLRP3<br/>Inflammasome"]
E["Caspase-1<br/>Activation"]
F["Gasdermin D<br/>Pyroptosis"]
G["IL-1beta / IL-18<br/>Release"]
H["Microglial<br/>Pyroptosis"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
F --> H
style A fill:#004d40,stroke:#80cbc4,color:#80cbc4
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix4 supports4 contradicts
Contradicts
Multiple P2X7 antagonists (AZD9056, CE-224,535, GSK1482160) failed in Phase 2 rheumatoid arthritis trials - major translational failure
Contradicts
ATP is rapidly degraded in circulation by ectonucleotidases; half-life in blood is minutes - peripheral ATP hypothesis physiologically questionable
Contradicts
P2X7 expressed on multiple cell types including neurons, astrocytes; global blockade may disrupt synaptic transmission
Contradicts
P2Y12, P2Y6 and other purinergic receptors may compensate for P2X7 inhibition, limiting efficacy
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — P2RX7
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for P2RX7 (P2X7 receptor) → PANX1 → NLRP3 → Caspase-1/Gasdermin D from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for P2RX7 (P2X7 receptor) → PANX1 → NLRP3 → Caspase-1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.3%
Volatility
Low
0.0069
Events (7d)
2
Price History
▲8.8%💾 Resource Usage
LLM Tokens
36,998
$0.1110
Total Cost
$0.1110
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF C57BL/6 mice receive intraperitoneal P2X7 antagonist (BBG, 50 mg/kg) 1 hour before LPS (5 mg/kg) injection THEN microglial NLRP3 inflammasome activation and serum IL-1β levels will decrease by >40% | Iba1+ microglia will show reduced NLRP3 immunofluorescence intensity and caspase-1 activity; serum IL-1β will drop from ~800 pg/mL to <480 pg/mL | — no observation — | pending | 0.65 |
| IF BV2 microglial cells are pretreated with 10 μM A438079 (P2X7 receptor antagonist) THEN ATP (5 mM)-induced pyroptosis will be reduced by >50% as measured by lactate dehydrogenase release, compared t | LDH release will decrease from ~80% (ATP alone) to <40% (ATP + antagonist), with concomitant reduction in Gasdermin D cleavage and cleaved caspase-1 levels | — no observation — | pending | 0.75 |
🔮 Falsifiable Predictions (2)
pendingconf 75%
IF BV2 microglial cells are pretreated with 10 μM A438079 (P2X7 receptor antagonist) THEN ATP (5 mM)-induced pyroptosis will be reduced by >50% as measured by lactate dehydrogenase release, compared to ATP-only controls, within 2 hours of stimulation.
Predicted outcome: LDH release will decrease from ~80% (ATP alone) to <40% (ATP + antagonist), with concomitant reduction in Gasdermin D cleavage and cleaved caspase-1 l
Falsification: No statistically significant difference in LDH release (p > 0.05) between P2X7 antagonist + ATP group and ATP-only group, or pyroptosis markers remain unchanged
pendingconf 65%
IF C57BL/6 mice receive intraperitoneal P2X7 antagonist (BBG, 50 mg/kg) 1 hour before LPS (5 mg/kg) injection THEN microglial NLRP3 inflammasome activation and serum IL-1β levels will decrease by >40% compared to LPS-only controls, within 24 hours post-injection.
Predicted outcome: Iba1+ microglia will show reduced NLRP3 immunofluorescence intensity and caspase-1 activity; serum IL-1β will drop from ~800 pg/mL to <480 pg/mL
Falsification: No reduction in microglial NLRP3 activation or serum IL-1β levels (difference <20%) between P2X7 antagonist-treated and LPS-only groups
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.